Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amylou C. Dueck, Briant Fruth, Anke C. Reinacher-Schick, Walter Peters, Robert J. Behrens, Christopher Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Dirk Arnold, Tyler Zemla, Clare A. Gatten, Peter Trask, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Fang-Shu Ou, Frank A. Sinicrope
Institutions: Mayo Clinic in Arizona, Mayo Clinic, St. Josef-Hospital, Ruhr University Bochum, Baylor Scott & White Health, University of Iowa Health Care, University of Colorado Anschutz, VCU Massey Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Nationwide Children's Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, University of Chicago Medical Center, University of Pittsburgh Medical Center, Asklepios Klinik Altona, Asklepios, Genentech, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162582658